5 Series C Biotech Investors — 5 Currently Deploying

Partner with visionary founders at the intersection of bold vision and relentless execution. Active investors seeking to be partners during the rapid growth stage of scaling journe…

Support domestic and international startups through capital provision and business collaboration, leveraging Dentsu Group's creative and strategic resources alongside global VC net…

Multi-stage venture capital firm that goes beyond traditional VC playbook by providing entrepreneurs support of a global ecosystem, connecting innovators everywhere.

Blue Ivy Ventures provides Yale alumni accredited investors access to diversified venture capital investments co-invested alongside leading VC firms, combining a curated annual fun…

How many series c biotech investors are actively deploying right now?

DryPowder tracks 5 series c biotech funds. Of these, 5 are currently deploying capital based on recent fund closes, portfolio activity, and partner signals. Use DryPowder's fund matching to see which ones fit your specific startup.

What should I look for when evaluating a series c biotech investor?

Prioritize thesis alignment first, then portfolio conflicts, check size fit, and deployment pace. A fund that invested in a direct competitor two years ago is unlikely to fund you regardless of fit. DryPowder tracks all of these for 5 series c biotech funds. Use fund matching to rank them before spending time on outreach.

How do I get a meeting with a series c biotech VC?

A warm intro is still the fastest path. Most series c biotech VCs on DryPowder do accept cold outreach or direct applications, but response rates vary widely by fund. Before reaching out, use DryPowder's AI matching to get a fit score and specific talking points. Founders who lead with thesis-aligned framing get significantly better response rates than those sending the same deck to every fund on a list.

What do Series C investors focus on during diligence?

Series C diligence is closer to private equity than early-stage venture. Investors focus on financial performance, market leadership, and a clear path to exit or profitability. Expect deep analysis of unit economics, competitive moats, and management team depth. The process typically takes 3-6 months and involves CFO-level engagement from both sides.

How many series c biotech investors should I be talking to at once?

Most fundraisers recommend a parallel process: identify 20-40 target investors but approach your highest-fit funds first. Of the 5 series c biotech funds currently deploying, not all will match your specific stage and sector. Use fund matching to find your top 10-15, approach those first, collect feedback, then go wider. Going to every fund simultaneously without qualifying first burns bridges and dilutes the urgency that helps close a round.

How is DryPowder different from building a VC list on LinkedIn or Crunchbase?

The fund list you build on LinkedIn or Crunchbase is roughly the same list every other founder is building. DryPowder adds three things a manual search cannot: deployment signals (which funds have recently closed new vehicles and are actively writing checks), AI thesis matching (which of the 5 series c biotech funds actually fits your specific startup, ranked by fit), and verified partner contact details. The goal is 15 targeted, thesis-aligned pitches instead of 150 generic ones.